Search This Blog

Monday, March 20, 2023

Connect Atopic Dermatitis Candidate Shows Rapid, Sustained Improvement in All Body Regions

 

  • Connect Biopharma Holdings Limited (NASDAQ: CNTB) announced post hoc data analysis from the Phase 2b CBP-201 global trial in moderate-to-severe atopic dermatitis (AD).

  • The data exhibited that CBP-201 led to rapid and sustained improvement in AD signs and symptoms across all four body regions, compared to the placebo.

  • EASI subscores improved in all four body regions across 16 weeks of treatment.

  • Improvements between 300 mg Q2W and Q4W were comparable. At Week 2, EASI decreased by -26.3% (head/neck), -26.4% (trunk), -21.6% (upper limbs), and -23.2% (lower limbs) for patients on CBP-201 300 mg Q4W treatment vs. -9.5% to -15.7% with placebo.

  • At Week 16, EASI decreased further to -69.2% (head and neck), -72.1% (trunk), -64.2% (upper limbs), and -68.5% (lower limbs) vs. -21.2% to -49.1% with placebo (p<0.01 per region).

  • Researchers also observed improvement for each classification of AD symptoms (signs): erythema, induration/papulation, lichenification, and excoriation, within each body region.

  • Concurrently, the company also announced data from Stage 1 of the ongoing pivotal CBP-201 China trial in moderate-to-severe atopic dermatitis (AD), exhibiting rapid relief from symptoms.

  • The study met primary and secondary endpoints, with mostly mild-to-moderate adverse effects reported.

  • At 16 weeks, more patients treated with CBP-201 achieved an IGA score of 0-1 (clear or almost clear skin) and a 2-point IGA reduction than those on placebo (30.3% vs. 7.5%).

  • 62.9% of CBP-201 patients achieved a 75% skin clearance (EASI-75), versus 23.4% in the placebo group and EASI-90 of (35.8% vs. 63.%).

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.